Practice Guidelines

Joint Guideline Released for Atrial Fibrillation



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2007 May 15;75(10):1565-1568.

Guideline source: American College of Cardiology, American Heart Association, European Society of Cardiology

Literature search described? Yes

Evidence rating system used? Yes

Published source: Journal of the American College of Cardiology, August 15, 2006

Available at: http://content.onlinejacc.org/cgi/content/full/48/4/854

Atrial fibrillation is the most common arrhythmia in clinical practice and causes substantial morbidity and mortality. The prevalence of the condition is estimated to be 0.4 to 1 percent, and atrial fibrillation hospitalizations have increased by more than 60 percent over the past two decades. The condition is associated with increased risk of stroke, heart failure, and all-cause mortality. Although atrial fibrillation is commonly associated with structural heart disease, many patients have no detectable heart disease. This guideline assists physicians in clinical decision making by describing options for the diagnosis and management of atrial fibrillation.

Evaluation

The clinical evaluation of patients with suspected atrial fibrillation (Table 1) includes characterizing the arrhythmia pattern as paroxysmal or persistent, determining its cause, and defining associated cardiac and extra-cardiac factors. The evaluation usually can be completed in one outpatient visit, unless the rhythm pattern cannot be specifically documented and additional monitoring is needed.

Table 1

Clinical Evaluation in Patients with Atrial Fibrillation

Minimal evaluation

History and physical examination to define:

Presence and nature of symptoms associated with atrial fibrillation

Clinical type of atrial fibrillation (e.g., first episode, paroxysmal, persistent, permanent)

Onset of the first symptomatic attack or date of discovery of atrial fibrillation

Frequency, duration, precipitating factors, and modes of termination of atrial fibrillation

Response to pharmacologic agents that have been administered

Presence of underlying heart disease or other reversible factors (e.g., hyperthyroidism, alcohol consumption)

Electrocardiography

To identify:

Rhythm (verify atrial fibrillation)

Left ventricular hypertrophy

P-wave duration and morphology or fibrillatory waves

Preexcitation

Bundle branch block

Prior myocardial infarction

Other atrial arrhythmias

To measure R-R, QRS, and Q-T intervals in conjunction with antiarrhythmic drug therapy

Transthoracic echocardiography to identify:

Valvular heart disease

Left and right atrial size

Left ventricular size and function

Peak right ventricular pressure (pulmonary hypertension)

Left ventricular hypertrophy

Left atrial thrombus (low sensitivity)

Pericardial disease

Blood tests (for a first episode of atrial fibrillation, when the ventricular rate is difficult to control) to evaluate thyroid, renal, and hepatic function

Additional testing (one or several tests may be necessary)

Six-minute walk test (if the adequacy of rate control is in question) Exercise test (if the adequacy of rate control is in question [permanent atrial fibrillation])

To reproduce exercise-induced atrial fibrillation

To exclude ischemia before treatment of selected patients with a type IC* antiarrhythmic drug

Holter monitor test or event recording (if diagnosis of the type of arrhythmia is in question) to evaluate rate control

Transesophageal echocardiography

To identify left atrial thrombus (in the left atrial appendage)

To guide cardioversion

Electrophysiologic study

To clarify the mechanism of wide-QRS-complex tachycardia

To identify a predisposing arrhythmia (e.g., atrial flutter, paroxysmal supraventricular tachycardia)

To seek sites for curative ablation or atrioventricular conduction block/modification

Chest radiography to evaluate lung parenchyma and pulmonary vasculature, when clinical findings suggest an abnormality


*—Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs. Source: American Heart Association.

Table 1   Clinical Evaluation in Patients with Atrial Fibrillation

View Table

Table 1

Clinical Evaluation in Patients with Atrial Fibrillation

Minimal evaluation

History and physical examination to define:

Presence and nature of symptoms associated with atrial fibrillation

Clinical type of atrial fibrillation (e.g., first episode, paroxysmal, persistent, permanent)

Onset of the first symptomatic attack or date of discovery of atrial fibrillation

Frequency, duration, precipitating factors, and modes of termination of atrial fibrillation

Response to pharmacologic agents that have been administered

Presence of underlying heart disease or other reversible factors (e.g., hyperthyroidism, alcohol consumption)

Electrocardiography

To identify:

Rhythm (verify atrial fibrillation)

Left ventricular hypertrophy

P-wave duration and morphology or fibrillatory waves

Preexcitation

Bundle branch block

Prior myocardial infarction

Other atrial arrhythmias

To measure R-R, QRS, and Q-T intervals in conjunction with antiarrhythmic drug therapy

Transthoracic echocardiography to identify:

Valvular heart disease

Left and right atrial size

Left ventricular size and function

Peak right ventricular pressure (pulmonary hypertension)

Left ventricular hypertrophy

Left atrial thrombus (low sensitivity)

Pericardial disease

Blood tests (for a first episode of atrial fibrillation, when the ventricular rate is difficult to control) to evaluate thyroid, renal, and hepatic function

Additional testing (one or several tests may be necessary)

Six-minute walk test (if the adequacy of rate control is in question) Exercise test (if the adequacy of rate control is in question [permanent atrial fibrillation])

To reproduce exercise-induced atrial fibrillation

To exclude ischemia before treatment of selected patients with a type IC* antiarrhythmic drug

Holter monitor test or event recording (if diagnosis of the type of arrhythmia is in question) to evaluate rate control

Transesophageal echocardiography

To identify left atrial thrombus (in the left atrial appendage)

To guide cardioversion

Electrophysiologic study

To clarify the mechanism of wide-QRS-complex tachycardia

To identify a predisposing arrhythmia (e.g., atrial flutter, paroxysmal supraventricular tachycardia)

To seek sites for curative ablation or atrioventricular conduction block/modification

Chest radiography to evaluate lung parenchyma and pulmonary vasculature, when clinical findings suggest an abnormality


*—Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs. Source: American Heart Association.

Physical examination findings suggestive of atrial fibrillation include irregular pulse, irregular jugular venous pulsations, variations in the intensity of the first heart sound, or absence of a fourth heart sound heard previously during sinus rhythm. A diagnosis must be confirmed with electrocardiography (ECG). Patients diagnosed with atrial fibrillation should receive two-dimensional Doppler echocardiography to assess left atrial and ventricular dimensions and left ventricular wall thickness and function and to exclude valvular heart disease and pericardial disease. Thyroid, renal, and hepatic functions should be measured during the evaluation.

If necessary, additional testing may include exercise or walking tests, a Holter monitor test or event recording, trans-esophageal echocardiography, and chest radiography.

Prevention of Thromboembolism

Antithrombotic therapy to prevent throm-boembolism is recommended for patients with atrial fibrillation unless the patient does not have heart disease or has contraindications to antithrombotic therapy. ECG may detect risk factors; however, the test's value for stratifying risk is limited because it is unclear whether the absence of abnormalities suggests low risk. Table 2 is a guideline for determining antithrombotic therapy in patients with atrial fibrillation. It is reasonable to regularly reevaluate the need for anticoagulation.

Table 2
Antithrombotic Therapy for Patients with Atrial Fibrillation

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

ANTICOAGULATION AGENTS

Therapy should be based on the patient's risk of stroke and bleeding. Patients with atrial fibrillation and a high risk of stroke who do not have a mechanical heart valve should receive a vitamin K antagonist. Aspirin is an alternative to a vitamin K antagonist in low-risk patients or in those who have contraindications to vitamin K antagonists.

The intensity of anticoagulation should be based on prevention of ischemic stroke versus avoidance of hemorrhagic complications. The recommended target is an International Normalized Ratio (INR) of between 2.0 and 3.0. INR should be measured at least weekly during therapy and monthly when anticoagulation is stable. Minimizing the risk of bleeding is particularly important in older patients.

INTERRUPTION OF ANTICOAGULATION

If anticoagulation is interrupted for more than one week because of surgery in high-risk patients, unfractionated or low-molecular-weight heparin may be administered to prevent thrombosis, although the effectiveness of these therapies has not been evaluated in controlled trials.

In patients undergoing percutaneous coronary intervention, anticoagulation may be interrupted to prevent bleeding; however, vitamin K anticoagulation should be reinstated as soon as possible after the procedure. Platelet-inhibitor drugs are valuable for preventing recurrent myocardial ischemia in patients undergoing percutaneous coronary intervention. Although aspirin may be given during the hiatus, maintenance therapy should consist of clopidogrel (Plavix) and warfarin (Coumadin); warfarin may be continued as monotherapy after nine to 12 months if no coronary events occur.

Cardioversion

Cardioversion (via drugs or electric shock) may be used to restore sinus rhythm in patients with persistent atrial fibrillation; however, there is a risk of thromboembolism unless anticoagulation is initiated before the procedure. Cardioversion is recommended for hemodynamically stable patients with atrial fibrillation symptoms that the patient feels are unacceptable (Figure 1). Recommended agents for pharmacologic cardioversion of atrial fibrillation are flecainide (Tambocor), dofetilide (Tikosyn), propafenone (Rythmol), and ibutilide (Corvert). Direct-current cardioversion is recommended if rapid ventricular response does not occur with pharmacologic cardioversion in patients with ongoing myocardial ischemia, symptomatic hypotension, angina, or heart failure.

Management of Atrial Fibrillation

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

Figure 1.



Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article